Alpha Synuclein - Pipeline Review, H1 2020

June 2020 | 150 pages | ID: A56DAC0B2B7AEN
Global Markets Direct

Abstracts

Alpha Synuclein - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Alpha Synuclein – Pipeline Review, H1 2020'; Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 57 molecules. Out of which approximately 47 molecules are developed by companies and remaining by the universities/institutes.

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

The report 'Alpha Synuclein – Pipeline Review, H1 2020' outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 9, 21 and 13 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neurodegenerative Diseases, Alzheimer's Disease, Lewy Body Dementia, Familial Amyloid Neuropathies, Amyloidosis, Constipation, Dementia, Dementia Associated With Alzheimer's Disease, Down Syndrome, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
• The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
• The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by ABL Bio Inc, H1 2020
Pipeline by AC Immune SA, H1 2020
Pipeline by AFFiRiS AG, H1 2020
Pipeline by Annovis Bio Inc, H1 2020
Pipeline by Aprinoia Therapeutics Inc, H1 2020
Pipeline by Arvinas Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Biogen Inc, H1 2020
Pipeline by Capo Therapeutics Inc, H1 2020
Pipeline by Declion Pharmaceuticals Inc, H1 2020
Pipeline by DegenRx BV, H1 2020
Pipeline by Denali Therapeutics Inc, H1 2020
Pipeline by Enterin Inc, H1 2020
Pipeline by Fulcrum Therapeutics Inc, H1 2020
Pipeline by Genmab AS, H1 2020
Pipeline by ICB International Inc, H1 2020
Pipeline by NeuBase Therapeutics Inc, H1 2020
Pipeline by Neurimmune Holding AG, H1 2020
Pipeline by Neuropore Therapies Inc, H1 2020
Pipeline by nLife Therapeutics SL, H1 2020
Pipeline by Prevail Therapeutics Inc, H1 2020
Pipeline by Priavoid GmbH, H1 2020
Pipeline by Primary Peptides Inc, H1 2020
Pipeline by Proclara Biosciences Inc, H1 2020
Pipeline by ProMIS Neurosciences Inc, H1 2020
Pipeline by Prothena Corp Plc, H1 2020
Pipeline by Seelos Therapeutics, Inc., H1 2020
Pipeline by Treventis Corp, H1 2020
Pipeline by UCB SA, H1 2020
Pipeline by United Neuroscience Ltd, H1 2020
Pipeline by Voyager Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AbbVie Inc
ABL Bio Inc
AC Immune SA
AFFiRiS AG
Annovis Bio Inc
Aprinoia Therapeutics Inc
Arvinas Inc
AstraZeneca Plc
Biogen Inc
Capo Therapeutics Inc
Declion Pharmaceuticals Inc
DegenRx BV
Denali Therapeutics Inc
Enterin Inc
Fulcrum Therapeutics Inc
Genmab AS
ICB International Inc
NeuBase Therapeutics Inc
Neurimmune Holding AG
Neuropore Therapies Inc
nLife Therapeutics SL
Prevail Therapeutics Inc
Priavoid GmbH
Primary Peptides Inc
Proclara Biosciences Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
Seelos Therapeutics, Inc.
Treventis Corp
UCB SA
United Neuroscience Ltd
Voyager Therapeutics Inc